AcelRx Pharmaceuticals Inc. [ACRX] Revenue clocked in at $2.80 million, down -48.38% YTD: What’s Next?

Related

AcelRx Pharmaceuticals Inc. [NASDAQ: ACRX] price surged by 27.63 percent to reach at $0.06. The company report on May 19, 2022 that AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA®.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (“AcelRx”), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported that the U.S. Food and Drug Administration (FDA) has recently modified the DSUVIA Risk Evaluation and Mitigation Strategies (REMS) requirements with respect to healthcare setting audits. The goal of the DSUVIA REMS program is to mitigate the risk of respiratory depression resulting from accidental exposure by ensuring that DSUVIA is dispensed only to patients in certified medically supervised healthcare settings.

On April 21, 2022, the FDA revised the DSUVIA REMS program to eliminate the 6-month healthcare setting audit requirement and reduce annual healthcare setting audits to a total of up to 400 sites that have received a shipment of DSUVIA in the past 6 months.  Previously, the DSUVIA REMS required AcelRx to audit all healthcare settings within six months of an initial DSUVIA order, and to then continue to audit all such sites annually thereafter (for sites continuing to order DSUVIA within a six-month period), with no limit to the number of sites audited.

A sum of 4000772 shares traded at recent session while its average daily volume was at 1.09M shares. AcelRx Pharmaceuticals Inc. shares reached a high of $0.31 and dropped to a low of $0.2295 until finishing in the latest session at $0.29.

The one-year ACRX stock forecast points to a potential upside of 93.18. The average equity rating for ACRX stock is currently 2.00, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on AcelRx Pharmaceuticals Inc. [ACRX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ACRX shares is $4.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ACRX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Credit Suisse have made an estimate for AcelRx Pharmaceuticals Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on July 20, 2020. While these analysts kept the previous recommendation, Credit Suisse dropped their target price from $7 to $2. The new note on the price target was released on November 11, 2019, representing the official price target for AcelRx Pharmaceuticals Inc. stock.

The Average True Range (ATR) for AcelRx Pharmaceuticals Inc. is set at 0.03, with the Price to Sales ratio for ACRX stock in the period of the last 12 months amounting to 12.89.

ACRX Stock Performance Analysis:

AcelRx Pharmaceuticals Inc. [ACRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 62.11. With this latest performance, ACRX shares gained by 10.72% in over the last four-week period, additionally sinking by -58.27% over the last 6 months – not to mention a drop of -77.41% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACRX stock in for the last two-week period is set at 61.61, with the RSI for the last a single of trading hit 70.23, and the three-weeks RSI is set at 55.25 for AcelRx Pharmaceuticals Inc. [ACRX]. The present Moving Average for the last 50 days of trading for this stock 0.2697, while it was recorded at 0.2316 for the last single week of trading, and 0.6317 for the last 200 days.

Insight into AcelRx Pharmaceuticals Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and AcelRx Pharmaceuticals Inc. [ACRX] shares currently have an operating margin of -1294.78 and a Gross Margin at -33.18. AcelRx Pharmaceuticals Inc.’s Net Margin is presently recorded at -1245.53.

AcelRx Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.90 and a Current Ratio set at 3.00.

AcelRx Pharmaceuticals Inc. [ACRX] Insider Position Details

There are presently around $5 million, or 20.80% of ACRX stock, in the hands of institutional investors. The top three institutional holders of ACRX stocks are: ROCK SPRINGS CAPITAL MANAGEMENT LP with ownership of 6,329,202, which is approximately 0.052% of the company’s market cap and around 1.70% of the total institutional ownership; D. E. SHAW & CO., INC., holding 3,808,993 shares of the stock with an approximate value of $0.86 million in ACRX stocks shares; and VANGUARD GROUP INC, currently with $0.79 million in ACRX stock with ownership of nearly -31.913% of the company’s market capitalization.

Positions in AcelRx Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 17 institutional holders increased their position in AcelRx Pharmaceuticals Inc. [NASDAQ:ACRX] by around 563,536 shares. Additionally, 24 investors decreased positions by around 10,763,380 shares, while 23 investors held positions by with 8,530,414 shares. The mentioned changes placed institutional holdings at 19,857,330 shares, according to the latest SEC report filing. ACRX stock had 7 new institutional investments in for a total of 192,040 shares, while 10 institutional investors sold positions of 8,615,139 shares during the same period.

[class^="wpforms-"]
[class^="wpforms-"]